vs
EXACT SCIENCES CORP（EXAS）与GREEN DOT CORP（GDOT）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是GREEN DOT CORP的1.8倍（$878.4M vs $498.6M），GREEN DOT CORP净利率更高（-9.4% vs -9.8%，领先0.4%），EXACT SCIENCES CORP同比增速更快（23.1% vs 14.3%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-76.3M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 6.5%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
绿点公司是总部位于美国得克萨斯州奥斯汀的金融科技及银行控股公司，按市值计算是全球规模最大的预付借记卡企业，同时经营支付平台业务，为Apple Cash、优步、Intuit提供技术平台支持。公司由史蒂夫·斯特赖特于1999年创立，最初面向青少年推出线上购物预付借记卡，2001年转型服务无银行账户及银行服务不足的群体。
EXAS vs GDOT — 直观对比
营收规模更大
EXAS
是对方的1.8倍
$498.6M
营收增速更快
EXAS
高出8.8%
14.3%
净利率更高
GDOT
高出0.4%
-9.8%
自由现金流更多
EXAS
多$196.8M
$-76.3M
两年增速更快
EXAS
近两年复合增速
6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $498.6M |
| 净利润 | $-86.0M | $-46.8M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | -5.5% |
| 净利率 | -9.8% | -9.4% |
| 营收同比 | 23.1% | 14.3% |
| 净利润同比 | 90.1% | -1017.6% |
| 每股收益（稀释后） | $-0.45 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASGDOT
| Q4 25 | $878.4M | $498.6M | ||
| Q3 25 | $850.7M | $472.2M | ||
| Q2 25 | $811.1M | $482.7M | ||
| Q1 25 | $706.8M | $537.2M | ||
| Q4 24 | $713.4M | $436.1M | ||
| Q3 24 | $708.7M | $393.7M | ||
| Q2 24 | $699.3M | $392.5M | ||
| Q1 24 | $637.5M | $439.3M |
净利润EXASGDOT
| Q4 25 | $-86.0M | $-46.8M | ||
| Q3 25 | $-19.6M | $-30.8M | ||
| Q2 25 | $-1.2M | $-47.0M | ||
| Q1 25 | $-101.2M | $25.8M | ||
| Q4 24 | $-864.6M | $5.1M | ||
| Q3 24 | $-38.2M | $-7.8M | ||
| Q2 24 | $-15.8M | $-28.7M | ||
| Q1 24 | $-110.2M | $4.8M |
毛利率EXASGDOT
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASGDOT
| Q4 25 | -9.4% | -5.5% | ||
| Q3 25 | -3.0% | -7.0% | ||
| Q2 25 | -0.3% | 2.8% | ||
| Q1 25 | -13.6% | 11.3% | ||
| Q4 24 | -122.8% | 3.3% | ||
| Q3 24 | -5.6% | -0.7% | ||
| Q2 24 | -3.8% | -6.0% | ||
| Q1 24 | -16.7% | 2.4% |
净利率EXASGDOT
| Q4 25 | -9.8% | -9.4% | ||
| Q3 25 | -2.3% | -6.5% | ||
| Q2 25 | -0.1% | -9.7% | ||
| Q1 25 | -14.3% | 4.8% | ||
| Q4 24 | -121.2% | 1.2% | ||
| Q3 24 | -5.4% | -2.0% | ||
| Q2 24 | -2.3% | -7.3% | ||
| Q1 24 | -17.3% | 1.1% |
每股收益（稀释后）EXASGDOT
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.60 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $890.2M |
| 总资产 | $5.9B | $6.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASGDOT
| Q4 25 | $964.7M | $1.4B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | $858.4M | $2.3B | ||
| Q1 25 | $786.2M | $1.8B | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $946.8M | $1.3B | ||
| Q1 24 | $652.1M | $1.1B |
股东权益EXASGDOT
| Q4 25 | $2.4B | $890.2M | ||
| Q3 25 | $2.5B | $913.3M | ||
| Q2 25 | $2.5B | $920.9M | ||
| Q1 25 | $2.4B | $947.7M | ||
| Q4 24 | $2.4B | $873.6M | ||
| Q3 24 | $3.2B | $932.2M | ||
| Q2 24 | $3.2B | $870.0M | ||
| Q1 24 | $3.1B | $870.6M |
总资产EXASGDOT
| Q4 25 | $5.9B | $6.0B | ||
| Q3 25 | $5.9B | $5.8B | ||
| Q2 25 | $5.8B | $5.6B | ||
| Q1 25 | $5.7B | $5.7B | ||
| Q4 24 | $5.9B | $5.4B | ||
| Q3 24 | $6.7B | $5.3B | ||
| Q2 24 | $6.7B | $5.5B | ||
| Q1 24 | $6.4B | $5.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $-62.5M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-76.3M |
| 自由现金流率自由现金流/营收 | 13.7% | -15.3% |
| 资本支出强度资本支出/营收 | 3.6% | 2.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $66.0M |
8季度趋势，按日历期对齐
经营现金流EXASGDOT
| Q4 25 | $151.7M | $-62.5M | ||
| Q3 25 | $219.9M | $23.3M | ||
| Q2 25 | $89.0M | $69.0M | ||
| Q1 25 | $30.8M | $108.7M | ||
| Q4 24 | $47.1M | $-23.0M | ||
| Q3 24 | $138.7M | $-16.3M | ||
| Q2 24 | $107.1M | $31.5M | ||
| Q1 24 | $-82.3M | $89.2M |
自由现金流EXASGDOT
| Q4 25 | $120.4M | $-76.3M | ||
| Q3 25 | $190.0M | $3.5M | ||
| Q2 25 | $46.7M | $49.5M | ||
| Q1 25 | $-365.0K | $89.3M | ||
| Q4 24 | $10.7M | $-45.1M | ||
| Q3 24 | $112.6M | $-37.0M | ||
| Q2 24 | $71.2M | $14.5M | ||
| Q1 24 | $-120.0M | $74.7M |
自由现金流率EXASGDOT
| Q4 25 | 13.7% | -15.3% | ||
| Q3 25 | 22.3% | 0.8% | ||
| Q2 25 | 5.8% | 10.3% | ||
| Q1 25 | -0.1% | 16.6% | ||
| Q4 24 | 1.5% | -10.3% | ||
| Q3 24 | 15.9% | -9.4% | ||
| Q2 24 | 10.2% | 3.7% | ||
| Q1 24 | -18.8% | 17.0% |
资本支出强度EXASGDOT
| Q4 25 | 3.6% | 2.8% | ||
| Q3 25 | 3.5% | 4.2% | ||
| Q2 25 | 5.2% | 4.0% | ||
| Q1 25 | 4.4% | 3.6% | ||
| Q4 24 | 5.1% | 5.1% | ||
| Q3 24 | 3.7% | 5.3% | ||
| Q2 24 | 5.1% | 4.3% | ||
| Q1 24 | 5.9% | 3.3% |
现金转化率EXASGDOT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 4.22× | ||
| Q4 24 | — | -4.51× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 18.77× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
GDOT
| B2B Services | $375.4M | 75% |
| Interchange Revenues | $44.4M | 9% |
| Processing And Settlement Service | $38.6M | 8% |
| Money Movement Services | $37.4M | 8% |
